PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: FOLEY & LARDER Attn. Peet, Richard, C. 3000 K Street, N.W. Suite 500 Washington, D.C. 20007-5109 UNITED STATES OF AMERICA

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Ĭ					
	Date of mailing (day/month/year) 01/08/2002				
Applicant's or agent's file reference					
023533/0139	FOR FURTHER ACTION See paragraphs 1 and 4 below				
International application No.	International filing date				
PCT/US 01/04832	(day/month/year) 15/02/2001				
Applicant					
BOARD OF TRUSTEES OF THE UNIVERSITY OF A	RKANSAS				
1. X The applicant is hereby notified that the International Search	h Report has been established and is transmitted herewith.				
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim					
When? The time limit for filling such amendments is norma International Search Report; however, for more de	ally 2 months from the date of transmittal of the etails, see the notes on the accompanying sheet.				
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41-22) 740.14.35	5				
For more detailed instructions, see the notes on the acco	ompanying sheet.				
2. The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.					
3. With regard to the protest against payment of (an) addition	onal fee(s) under Rule 40.2, the applicant is notified that:				
the protest together with the decision thereon has bee applicant's request to forward the texts of both the pro	en transmitted to the International Bureau together with the elest and the decision thereon to the designated Offices.				
no decision has been made yet on the protest; the ap	plicant will be notified as soon as a decision is made.				
4. Further action(s): The applicant is reminded of the following:					

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentiaan 2

priority date or could not be elected because they are not bound by Chapter II.

NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Authorized officer

Tanja R}hrmund

Form PCT/ISA/220 (July 1998)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new:
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]:
 "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 023533/0139	FOR FURTHER see Notification (Form PCT/ISA/2	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 01/04832	15/02/2001	15/02/2000
Applicant BOARD OF TRUSTEES OF THE	UNIVERSITY OF ARKANSAS	
according to Article 18. A copy is being tra	_	thority and is transmitted to the applicant
This International Search Report consists It is also accompanied by	of a total of sheets. a copy of each prior art document cited in this	s report.
	international search was carried out on the baless otherwise indicated under this item.	asis of the international application in the
the international search w Authority (Rule 23.1(b)).	vas carried out on the basis of a translation of	the international application furnished to this
b. With regard to any nucleotide and was carried out on the basis of the contained in the internation filed together with the internation furnished subsequently to the statement that the sul international application a	e sequence listing: onal application in written form. emational application in computer readable for o this Authority in written form. o this Authority in computer readble form. beguently furnished written sequence listing as filed has been furnished.	
Certain claims were foul Unity of invention is lace	ind unsearchable (See Box I). king (see Box II).	•
X the text has been establis		RECEPTOR AND USE IN TREATING
the text has been established	ubmitted by the applicant. shed, according to Rule 38.2(b), by this Autho e date of mailing of this international search re	rity as it appears in Box III. The applicant may, eport, submit comments to this Authority.
as suggested by the app		None of the figures.

Form PCT/ISA/210 (first sheet) (July 1998)

Please forward to

PHOENIX SCANNING

CENTRAL UNIT RECEIVING SECTION

The attached document should be indexed and scanned for PHOENIX with number XS SA334063 14 MA

DocCode ABSTMOD Group PCTISA

Sent by: Tanja Rührmund

Date request: 22/07/2002

International application No.

PCT/US 01/04832

Box III TEXT OF THE ABSTRACT (Continuation fitem 5 of the first sheet)

A method of treating a human having airway or vascular disease comprises administering to at least one cell type selected from airway epithelial cells, airway smooth muscle cells, blood

vessel endothelial cells, and blood vessel smooth muscle cells, a first composition comprising a vector comprising a DNA sequence encoding a B_2AR (B_2 -adrenergic receptor)

or a mutant thereof, operably linked to a promoter that is functional in at least one of said cells said subject, and optionally a second composition comprising at least one β_2 -adrenergic

agonist. Pharmaceutical compositions comprising the vector comprising a DNA sequence encoding a β_2AR or a mutant thereof, operably linked to a promoter that is functional in at least one of the cells of the subject and kits containing these compositions as well as. An in vitro method of expressing the β_2AR gene in mammalian cells and a method of evaluating the effect of pharmacological compounds on the expression of the β_2AR gene are disclosed.

International Application No PCT/US 01/04832

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K48/00 C12M C12N15/86 A61P11/06. A61P11/08 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C07K C12N IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ° X WO 97 35963 A (DAINIPPON PHARMACEUICAL CO. 6,7, 40-43 LTD.) 2 October 1997 (1997-10-02) abstract TIMMERMANN B ET AL: "beta.-2 Adrenoceptor 1 - 43Α genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study" KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 53, no. 6, June 1998 (1998-06), pages 1455-1460, XP002106248 ISSN: 0085-2538 abstract Patent family members are listed in annex. Further documents are listed in the continuation of box C. X Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but *A* document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 01/08/2002 17 July 2002 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Siatou, E

1

International Application No
PCT/US 01/04832

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	• • • • • • • • • • • • • • • • • • • •	
1	GREEN S ET AL: "Influence of beta-2 adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells" AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US,	1-43
	vol. 1, no. 13, 1 July 1995 (1995-07-01), pages 25-33, XP002079183 ISSN: 1044-1549 abstract	
A	LIGGETT S: "Polymorphisms of the beta-2 adrenergic receptor and asthma" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 156, no. 4, PART 2, October 1997 (1997-10), pages S156-S162, XP002106240 ISSN: 1073-449X abstract	1-43
		:
•		
	·	

1

International application No. PCT/US 01/04832

INTERNATIONAL SEARCH REPORT

B x I Observations wher certain claims w r found unsearchable (Continuation f it m 1 f first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-5, 8-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Information on patent family members

International Application No
PCT/US 01/04832

Pa cited	tent document in search report		Publication date		Patent family member(s)		Publication date
	9735963	Α	02-10-1997	AU WO	1945297 9735963	A A1	17-10-1997 02-10-1997
							•
				•			